妊娠期物质使用普筛流程的实施
该质量改进项目在城市三级医院门诊产前诊所实施基于5Ps工具和SBIRT模型的妊娠期物质使用普筛。19个月内抽样733次就诊,618次(84%)完成筛查,其中124次(20%)阳性;最后6个月筛查率超过90%目标,但医生简短干预记录率从80%降至50%。结论认为可持续的普筛流程可行,但需维持医生对阳性筛查的干预记录。
要点
- 5Ps工具联合SBIRT模型可在产前门诊实现妊娠期物质使用普筛。
- 19个月抽样733次就诊,筛查完成率84%,阳性率20%。
- 筛查率最后6个月超90%目标,但医生干预记录率由80%降至50%。
核心结论
- 在大型产前实践中实施可持续且可推广的物质使用筛查流程是可行的,并有助于识别未被已知存在风险的患者。
- 需要进一步努力评估如何维持医生对阳性筛查结果的干预记录。
研究设计与样本
- 质量改进框架,包括流程建模、利益相关者分析和计划-执行-研究-处理(PDSA)循环。
- 在城市三级医院门诊产前诊所实施基于改良5Ps筛查工具(父母、同伴、伴侣、过去、现在)的普筛,并采用基于SBIRT(筛查、简短干预、转诊治疗)模型的操作流程。
- 主要结局指标为接受物质使用筛查的患者百分比,目标为90%;次要结局指标为筛查阳性百分比及阳性筛查导致医生记录简短干预的百分比。
- 实施周期19个月,抽样733次患者就诊。
主要发现
- 618次(84%)就诊完成了物质使用筛查。
- 在数据收集的最后6个月,筛查率超过了90%的合格患者目标。
- 618次完成筛查中,124次(20%)筛查阳性。
- 医生对阳性筛查患者记录简短干预的比例在实施最后阶段达到80%,但在研究期结束时下降至50%。
关键数值与推荐
- 主要结局目标:筛查90%的合格患者。
- 筛查完成率:618/733(84%)。
- 筛查阳性率:124/618(20%)。
- 医生简短干预记录率:最后阶段80%,研究结束时50%。
临床怎么用
- 可在产前门诊采用改良5Ps工具和SBIRT模型建立妊娠期物质使用普筛流程。
- 实施中需关注医生对阳性筛查结果记录简短干预的可持续性。
局限性
- 研究为单中心质量改进项目,实施周期19个月,抽样733次就诊。
- 医生简短干预记录率在研究期结束时下降至50%,提示可持续性挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To implement a standardized universal substance use screening process in an outpatient prenatal clinic at an urban tertiary care hospital. METHODS: Using a quality-improvement framework that involved process modeling, stakeholder analyses, and plan-do-study-act cycles, we implemented universal substance use screening for prenatal patients using a modified 5Ps screening tool (Parents, Peers, Partner, Past, Present). Implementation included an operational workflow based on the SBIRT (Screening, Brief Intervention, Referral to Treatment) model. The primary outcome measure was percentage of patients who were screened for substance use, with a goal of 90% screened. Secondary outcome measures were percentage who screened positive and percentage of the time a positive screen resulted in documentation of a brief intervention by a health care practitioner. RESULTS: Over a 19-month implementation period, 733 patient encounters were sampled. A substance use screen was completed in 618 (84%). We exceeded our goal of screening 90% of eligible patients for the final 6 months of data collection. Of the 618 completed screens, 124 (20%) screened positive. Health care practitioner documentation of brief interventions for patients with a positive screen reached 80% in the final phase of implementation, but then declined to 50% by the completion of the study period. CONCLUSION: A sustainable and generalizable process to carry out substance use screening within a large prenatal practice is feasible, and assisted with identification of patients not known to be at risk. Further efforts are needed to evaluate how to sustain health care practitioner documentation of intervention in response to positive screens.
引用
- Ulrich M, Memmo EP, Cruz A, et al. Implementation of a Universal Screening Process for Substance Use in Pregnancy. Obstet Gynecol. 2021. PMID: 33706353. doi:10.1097/AOG.0000000000004305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。